Advertisement

Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C

Published:September 13, 2012DOI:https://doi.org/10.1016/j.clinthera.2012.08.009

      Abstract

      Background

      Boceprevir is a protease inhibitor indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in combination with peginterferon and ribavirin for treatment-naive patients and those who previously failed to improve with interferon and ribavirin treatment.

      Objective

      This article provides an overview of the mechanism of action, pharmacologic and pharmacokinetic properties, clinical efficacy, and tolerability of boceprevir.

      Methods

      Relevant information was identified through a search of PubMed (1990–July 2012), EMBASE (1990–July 2012), International Pharmaceutical Abstracts (1970–July 2012), and Google Scholar using the key words boceprevir, SCH 503034, non-structural protein 3 (NS3) serine protease inhibitor, and direct-acting antiviral agent (DAA). Additional information was obtained from the US Food and Drug Administration's Web site, review of the reference lists of identified articles, and posters and abstracts from scientific meetings.

      Results

      Clinical efficacy of boceprevir was assessed in 2 Phase III trials, Serine Protease Inhibitor Therapy–2 (SPRINT-2) for treatment-naive patients and Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 (RESPOND-2) for treatment-experienced patients. In SPRINT-2, patients were randomized to receive peginterferon + ribavirin (PR) or peginterferon + ribavirin + boceprevir (PRB); duration of boceprevir therapy varied from 24, 32, to 44 weeks on the basis of HCV RNA results. The primary endpoint was achievement of sustained virologic response (SVR; lower limit of detection, 9.3 IU/mL). The addition of boceprevir was shown to be superior, with overall SVR rates ranging from 63% to 66% compared with 38% with PR (P < 0.001). Results of SVR in SPRINT-2 were also reorganized to monitor SVRs in black and non-black patients. Treatment-experienced patients were assessed in RESPOND-2; however, null responders were excluded. Patients were again randomized to PR or PRB; duration of boceprevir therapy varied from 32 to 44 weeks on the basis of HCV RNA results. SVR was significantly higher in patients receiving boceprevir (59%–66% vs 21% with PR; P < 0.001). This benefit was seen in both previous nonresponders (SVR, 40%–52% vs 7% with PR), as well as previous relapsers (SVR, 69%–75% vs 29% with PR). Importantly, SVR could be attained with a shortened course of therapy in almost one half of all treated patients in SPRINT-2 (44%) and RESPOND-2 (46%).

      Conclusions

      Boceprevir was well tolerated in clinical trials and a welcomed addition to our HCV armamentarium.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Daniels D.
        • Grytdal S.
        • Wasley A.
        • Centers for Disease Control and Prevention (CDC)
        Surveillance for acute viral hepatitis—United States, 2007.
        MMWR Surveill Summ. 2009; 58: 1-27
        • Workowski K.A.
        • Berman S.
        • Centers for Disease Control and Prevention (CDC)
        Sexually transmitted diseases treatment guidelines, 2010.
        MMWR Recomm Rep. 2010; 59 ([published correction appears in MMWR Recomm Rep. 2011;60:18]): 1-110
        • Desai A.P.
        • Reau N.
        Naives, nonresponders, relapsers: who is there left to treat?.
        Clin Liver Dis. 2011; 15: 483-495
        • Foote B.S.
        • Spooner L.M.
        • Belliveau P.P.
        Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
        Ann Pharmacother. 2011; 45: 1085-1093
        • Jazwinski A.B.
        • Muir A.J.
        Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.
        Gastroenterol Clin North Am. 2011; 40: 481-494
        • Seden K.
        • Back D.
        Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
        Curr Opin HIV AIDS. 2011; 6: 514-526
        • Hofmann W.P.
        • Zeuzem S.
        A new standard of care for the treatment of chronic HCV infection.
        Nat Rev Gastroenterol Hepatol. 2011; 8: 257-264
        • Njoroge F.G.
        • Chen K.X.
        • Shih N.Y.
        • Piwinski J.J.
        Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
        Acc Chem Res. 2008; 41: 50-59
        • Flint M.
        • Mullen S.
        • Deatly A.M.
        • et al.
        Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
        Antimicrob Agents Chemother. 2009; 53: 401-411
        • Kwo P.Y.
        • Zhao R.
        Boceprevir: a user's guide.
        Clin Liver Dis. 2011; 15: 537-553
        • Rice C.M.
        New insights into HCV replication: potential antiviral targets.
        Top Antivir Med. 2011; 19: 117-120
        • Gravitz L.
        Introduction: a smouldering public-health crisis.
        Nature. 2011; 474: S2-S4
        • Bacon B.R.
        • Gordon S.C.
        • Lawitz E.
        • et al.
        Boceprevir for previously treated chronic HCV genotype 1 infection.
        N Engl J Med. 2011; 364: 1207-1217
        • Venkatraman S.
        • Blackman M.
        • Wu N.
        • et al.
        Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease.
        Bioorg Med Chem. 2009; 17: 4486-4495
        • Ciesek S.
        • Manns M.P.
        Hepatitis in 2010: the dawn of a new era in HCV therapy.
        Nat Rev Gastroenterol Hepatol. 2011; 8: 69-71
        • Poordad F.
        Big changes are coming in hepatitis C.
        Curr Gastroenterol Rep. 2011; 13: 72-77
        • Liu-Young G.
        • Kozal M.J.
        Hepatitis C protease and polymerase inhibitors in development.
        AIDS Patient Care STDS. 2008; 22: 449-457
      1. Victrelis.
        ([package insert]) Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Whitehouse Station, NJ2011 (Accessed July 30, 2012)
      2. Incivek.
        ([package insert]) Vertex Pharmaceuticals Incorporated, Cambridge, MA2012 (Accessed July 30, 2012)
        • Dore G.J.
        • Matthews G.V.
        • Rockstroh J.
        Future of hepatitis C therapy: development of direct-acting antivirals.
        Curr Opin HIV AIDS. 2011; 6: 508-513
        • Milazzo L.
        • Antinori S.
        STAT-C: a full revolution or just a step forward?.
        Lancet. 2010; 376: 662-663
        • Opar A.
        Excitement grows for potential revolution in hepatitis C virus treatment.
        Nat Rev Drug Discov. 2010; 9: 501-503
        • Rice C.
        Perspective: miles to go before we sleep.
        Nature. 2011; 474: S8
        • Pawlotsky J.M.
        The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.
        Gastroenterology. 2011; 140: 746-754
        • Poordad F.
        • McCone Jr, J.
        • Bacon B.R.
        • et al.
        Boceprevir for untreated chronic HCV genotype 1 infection.
        N Engl J Med. 2011; 364: 1195-1206
        • Kwo P.Y.
        • Lawitz E.J.
        • McCone J.
        • et al.
        Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre Phase 2 trial.
        Lancet. 2010; 376: 705-716
        • Chen K.X.
        • Njoroge F.G.
        The journey to the discovery of boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
        Prog Med Chem. 2010; 49: 1-36
        • Venkatraman S.
        • Bogen S.L.
        • Arasppan A.
        • et al.
        Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
        J Med Chem. 2006; 49: 6074-6086
      3. Zhang J, Gupta S, Rouzier R, et al. Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation. Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2005; San Francisco, Calif. Abstract 862.

      4. Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-α). Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2005; San Francisco, Calif. Abstract 94.

      5. Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype-1 peg-intron non-responders: Phase IB results. Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2005; San Francisco, Calif. Abstract 201.

      6. Preston R, Alonso A, Feely W, et al. SCH 503034, an oral HCV protease inhibitor, is well-tolerated in patients with varying degrees of hepatic impairment. Abstract presented at: 42nd Annual Meeting of the European Association for the Study of the Liver; April 11–15, 2007; Barcelona, Spain. Abstract 545.

        • Treitel M.
        • Marbury T.
        • Preston R.A.
        • et al.
        Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
        Clin Pharmacokinet. 2012; 51: 619-628
        • Ghosal A.
        • Yuan Y.
        • Tong W.
        • et al.
        Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.
        Drug Metab Dispos. 2011; 39: 510-521
        • Lange C.M.
        • Sarrazin C.
        • Zeuzem S.
        Review article: specifically targeted anti-viral therapy for hepatitis C—a new era in therapy.
        Aliment Pharmacol Ther. 2010; 32: 14-28
        • Vermehren J.
        • Sarrazin C.
        New HCV therapies on the horizon.
        Clin Microbiol Infect. 2011; 17: 122-134
        • Nelson D.R.
        The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
        Liver Int. 2011; 31: 53-57
        • Asselah T.
        • Marcellin P.
        New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
        Liver Int. 2011; 31: 68-77
        • Susser S.
        • Welsch C.
        • Wang Y.
        • et al.
        Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
        Hepatology. 2009; 50: 1709-1718
        • Pawlotsky J.M.
        Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
        Hepatology. 2011; 53: 1742-1751
        • Jensen D.M.
        A new era of hepatitis C therapy.
        N Engl J Med. 2011; 364: 1272-1274
        • Soriano V.
        • Vispo E.
        • Poveda E.
        • et al.
        Directly acting antivirals against hepatitis C virus.
        J Antimicrob Chemother. 2011; 66: 1673-1686
        • Pockros P.J.
        Drugs in development for viral hepatitis: care and caution.
        Drugs. 2011; 71: 263-271
        • Maddur H.
        • Kwo P.Y.
        Boceprevir.
        Hepatology. 2011; 54: 2254-2257
        • Asselah T.
        A sprint to increase response to HCV treatment: expectancies but caution.
        J Hepatol. 2011; 55: 1154-1158
        • Charlton M.
        • Leise M.D.
        Boceprevir (Victrelis) for HCV: V is for victory and very complex.
        Hepatology. 2011; 54: 1882-1886
        • Sarrazin C.
        • Rouzier R.
        • Wagner F.
        • et al.
        SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
        Gastroenterology. 2007; 132: 1270-1278
        • Degertekin B.
        • Lok A.S.
        Update on viral hepatitis: 2007.
        Curr Opin Gastroenterol. 2008; 24: 306-311
        • Pawlotsky J.M.
        Treatment of hepatitis C: don't put all your eggs in one basket!.
        Gastroenterology. 2007; 132: 1611-1615
        • Pockros P.J.
        Drugs in development for chronic hepatitis C: a promising future.
        Expert Opin Biol Ther. 2011; 11: 1611-1622
        • Schlutter J.
        Therapeutics: new drugs hit the target.
        Nature. 2011; 474: S5-S7
        • US Dept of Health and Human Services
        NDA 202258.
        (Accessed July 31, 2012)
        • Tungol A.
        • Rademacher K.
        • Schafer J.A.
        Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
        J Manag Care Pharm. 2011; 17: 685-694
        • Limave A.R.
        • Draganov P.V.
        • Cabrera R.
        Boceprevir for chronic HCV genotype 1 infection.
        N Engl J Med. 2011; 365: 176
        • Kuntzen T.
        • Timm J.
        • Berical A.
        • et al.
        Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
        Hepatology. 2008; 48: 1769-1778
        • Bartels D.J.
        • Zhou Y.
        • Zhang E.Z.
        • et al.
        Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naïve subjects.
        J Infect Dis. 2008; 198: 800-807
        • Susser S.
        • Vermehren J.
        • Forestier N.
        • et al.
        Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
        J Clin Virol. 2011; 52: 321-327
        • Tong X.
        • Bogen S.
        • Chase R.
        • et al.
        Characterization of resistance mutations against HCV ketoamide protease inhibitors.
        Antiviral Res. 2008; 77: 177-185
        • Cubero M.
        • Esteban J.I.
        • Otero T.
        • et al.
        Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
        Virology. 2008; 370: 237-245
        • Curry S.
        • Qiu P.
        • Tong X.
        Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay.
        J Virol Methods. 2008; 153: 156-162
        • Romano K.P.
        • Ali A.
        • Royer W.E.
        • Schiffer C.A.
        Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.
        Proc Natl Acad Sci U S A. 2010; 107: 20986-200991
        • Welzel T.M.
        • Zeuzem S.
        Mixing and matching drugs: what makes sense?.
        Clin Liver Dis. 2011; 15: 657-664
        • Chevaliez S.
        • Asselah T.
        Mechanisms of non-response to antiviral treatment in chronic hepatitis C.
        Clin Res Hepatol Gastroenterol. 2011; 35: S31-S41
        • Chase R.
        • Skelton A.
        • Xia E.
        • et al.
        A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
        Antiviral Res. 2009; 84: 178-184
        • Tong X.
        • Arasappan A.
        • Bennett F.
        • et al.
        Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
        Antimicrob Agents Chemother. 2010; 54: 2365-2370
        • Brown N.A.
        Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors.
        Expert Opin Investig Drugs. 2009; 18: 709-725
        • Nelson D.R.
        Hepatitis C drug development at a crossroads.
        Hepatology. 2009; 50: 997-999
        • Fonseca-Coronado S.
        • Escobar-Gutierrez A.
        • Ruiz-Tovar K.
        • et al.
        Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals.
        J Clin Microbiol. 2012; 50: 281-287
        • Bae A.
        • Sun S.C.
        • Qi X.
        • et al.
        Susceptibility of treatment-naïve hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
        Antimicrob Agents Chemother. 2010; 54: 5288-5297
        • Lenz O.
        • Verbinnen T.
        • Lin T.I.
        • et al.
        In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
        Antimicrob Agents Chemother. 2010; 54: 1878-1887
        • Vachon M.L.
        • Dieterich D.T.
        The HIV/HCV-coinfected patient and new treatment options.
        Clin Liver Dis. 2011; 15: 585-596
        • Charlton M.
        Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents—a potentially lethal cocktail.
        Hepatology. 2011; 54: 3-5
        • Seden K.
        • Back D.
        • Khoo S.
        New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
        J Antimicrob Chemother. 2012; 65: 1079-1085
        • Muir A.J.
        Telaprevir for the treatment of chronic hepatitis C infection.
        Expert Rev Anti Infect Ther. 2011; 9: 1105-1114
        • Weiss J.J.
        • Alcorn M.C.
        • Rabkin J.G.
        • Dieterich D.T.
        The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice.
        J Hepatol. 2012; 56: 503-504
        • Harrington P.R.
        • Zeng W.
        • Naeger L.K.
        Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
        Hepatology. 2012; 55: 1048-1057
        • Cammà C.
        • Petta S.
        • Enea M.
        • et al.
        Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
        Hepatology. 2012 Mar 27; ([Epub ahead of print].)
        • Messori A.
        • Fadda V.
        • Maratea D.
        • Trippoli S.
        Effect of discounting on estimation of benefits determined by hepatitis C treatment.
        World J Gastroenterol. 2012; 18: 3032-3034
      7. 2011 Drug Topics Red Book.
        Thomson Medical Economics, Montvale, NJ2011